医学理论与实践
醫學理論與實踐
의학이론여실천
The Journal of Medical Theory and Practice
2015年
8期
986-988
,共3页
辛伐他汀%厄贝沙坦%原发性高血压%糖尿病
辛伐他汀%阨貝沙坦%原髮性高血壓%糖尿病
신벌타정%액패사탄%원발성고혈압%당뇨병
Simvastatin%Irbesartan%Hypertension%Diabetes
目的：观察并分析辛伐他汀联合厄贝沙坦对原发性高血压合并糖尿病患者左心室肥厚的疗效与安全性。方法：将105例原发性高血压合并糖尿病患者随机分为观察组和对照组。对照组52例给予辛伐他汀治疗，观察组53例给予辛伐他汀联合厄贝沙坦治疗，对比分析两组患者左心室肥厚的疗效与安全性。结果：治疗8个月后，两组患者治疗后的 SBP 、DBP 、LVDd 、IVST 、LVPWT 、LVMI 均比治疗前降低，差异均有统计学意义（P ＜0．05）。观察组治疗后的SBP 、DBP 、LVMI 显著低于对照组，差异均有统计学意义（P＜0．05）。观察组的总有效率（90．6％）比对照组（75．0％）高，差异均有统计学意义（P＜0．05）。观察组的不良反应发生率（7．55％）比对照组（19．23％）低，差异有统计学意义（P＜0．05）。结论：辛伐他汀联合厄贝沙坦对原发性高血压合并糖尿病患者左心室肥厚的疗效显著，安全性高，值得临床推广使用。
目的：觀察併分析辛伐他汀聯閤阨貝沙坦對原髮性高血壓閤併糖尿病患者左心室肥厚的療效與安全性。方法：將105例原髮性高血壓閤併糖尿病患者隨機分為觀察組和對照組。對照組52例給予辛伐他汀治療，觀察組53例給予辛伐他汀聯閤阨貝沙坦治療，對比分析兩組患者左心室肥厚的療效與安全性。結果：治療8箇月後，兩組患者治療後的 SBP 、DBP 、LVDd 、IVST 、LVPWT 、LVMI 均比治療前降低，差異均有統計學意義（P ＜0．05）。觀察組治療後的SBP 、DBP 、LVMI 顯著低于對照組，差異均有統計學意義（P＜0．05）。觀察組的總有效率（90．6％）比對照組（75．0％）高，差異均有統計學意義（P＜0．05）。觀察組的不良反應髮生率（7．55％）比對照組（19．23％）低，差異有統計學意義（P＜0．05）。結論：辛伐他汀聯閤阨貝沙坦對原髮性高血壓閤併糖尿病患者左心室肥厚的療效顯著，安全性高，值得臨床推廣使用。
목적：관찰병분석신벌타정연합액패사탄대원발성고혈압합병당뇨병환자좌심실비후적료효여안전성。방법：장105례원발성고혈압합병당뇨병환자수궤분위관찰조화대조조。대조조52례급여신벌타정치료，관찰조53례급여신벌타정연합액패사탄치료，대비분석량조환자좌심실비후적료효여안전성。결과：치료8개월후，량조환자치료후적 SBP 、DBP 、LVDd 、IVST 、LVPWT 、LVMI 균비치료전강저，차이균유통계학의의（P ＜0．05）。관찰조치료후적SBP 、DBP 、LVMI 현저저우대조조，차이균유통계학의의（P＜0．05）。관찰조적총유효솔（90．6％）비대조조（75．0％）고，차이균유통계학의의（P＜0．05）。관찰조적불량반응발생솔（7．55％）비대조조（19．23％）저，차이유통계학의의（P＜0．05）。결론：신벌타정연합액패사탄대원발성고혈압합병당뇨병환자좌심실비후적료효현저，안전성고，치득림상추엄사용。
Objective :To study the clinical effects and safety of simvastatin combined with irbesartan on left ventricular hypertrophy in hypertension patients with diabetes .Methods :A total of 105 hypertension patients with diabetes were randomly divided into observation group and control group .52 patients in control group were treated by simvastatin and 53 patients in observation group were treated by simvastatin combined with irbesartan .The clinical efficacy and safety were compared between two groups .Results :The SBP ,DBP ,LVDd ,IVST ,LVPWT ,LVMI in both groups were significantly decreased after 8 months treatment(P< 0 .05) .The SBP ,DBP and LVMI in observation group were signif‐icantly lower than those in control group ,after treatment(P< 0 .05) .The clinical efficacy rate was 90 .6% in observa‐tion group which was significantly higher than 75 .0% in control group(P< 0 .05) .The adverse reaction rate in obser‐vation group was 7 .55% which was significantly lower than 19 .23% in control group(P< 0 .05) .Conclusion :Simvasta‐tin combined with irbesartan has a great clinical efficacy and safety in the treatment of left ventricular hypertrophy in hypertension patients with diabetes ,makes it worth for clinical application .
